Oculis Holding AG announced that the final patient visit has been completed in the DIAMOND phase 3 program assessing OCS-01, ...

A new study has found that prior authorizations for anti–vascular endothelial growth factor treatment led to a delay in patient care for most patients. Anti-VEGF treatments have been used in patients ...

At the 131st Congress of the French Society of Ophthalmology in Paris, France, the role of second-generation intravitreal anti-VEGF injections compared to corticosteroid injections in treating ...

Please provide your email address to receive an email when new articles are posted on . DRCR Retina Network trials have made numerous contributions to diabetic retinopathy and diabetic macular edema ...

The FDA’s decision to extend the labeled duration of faricimab use in RVO beyond 6 months primarily reflects accumulated ...

New non-human primate (NHP) data for VLTR-559, a long-acting anti-VEGF therapy that could reduce the dosing frequency for the treatment of wet age-related macular degeneration (AMD) to twice-yearly, ...

At least 20 million Americans ages 40 and older have age-related macular degeneration, and the threat posed by the vision-robbing condition will only grow larger as the population ages. Despite the ...

In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab ...

With three potential blockbuster drugs for retinal disease receiving regulatory approval in 2023, 2024 may feel quiet by comparison for the field. However, retina specialists may feel like they have ...